Valuing the health states associated with breast cancer screening programmes:a systematic review of economic measures by Bromley, Hannah et al.
 
 
University of Birmingham
Valuing the health states associated with breast
cancer screening programmes
Bromley, Hannah; Petrie, Dennis ; Mann, G Bruce ;  Nickson, Carolyn; Rea, Daniel; Roberts,
Tracy
DOI:
10.1016/j.socscimed.2019.03.028
License:
Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Bromley, H, Petrie, D, Mann, GB, Nickson, C, Rea, D & Roberts, T 2019, 'Valuing the health states associated
with breast cancer screening programmes: a systematic review of economic measures', Social Science and
Medicine, vol. 228, pp. 142-154. https://doi.org/10.1016/j.socscimed.2019.03.028
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked for eligibility: 19/03/2019
Bromley, H. et al (2019) Valuing the health states associated with breast cancer screening programmes: A systematic review of economic
measures, Social Science & Medicine, 228: 142-154; https://doi.org/10.1016/j.socscimed.2019.03.028
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 14. Jun. 2020
1 
 
Valuing the health states associated with breast cancer screening programmes: a systematic 1 
review of economic measures  2 
 3 
Abstract 4 
 5 
Policy decisions regarding breast cancer screening and treatment programmes may be misplaced  6 
unless the decision process includes the appropriate utilities and disutilities of mammography 7 
screening and its sequelae. The objectives of this study were to critically review how economic 8 
evaluations have valued the health states associated with breast cancer screening, and appraise the 9 
primary evidence informing health state utility values (cardinal measures of quality of life). A 10 
systematic review was conducted up to September 2018 of studies that elicited or used utilities 11 
relevant to mammography screening. The methods used to elicit utilities and the quality of the 12 
reported values were tabulated and analysed narratively.  13 
40 economic evaluations of breast cancer screening programmes and 10 primary studies 14 
measuring utilities for health states associated with mammography were reviewed in full. The 15 
economic evaluations made different assumptions about the measures used, duration applied and the 16 
sequalae included in each health state. 22 evaluations referenced utilities based on assumptions or 17 
used measures that were not methodologically appropriate. There was significant heterogeneity in the 18 
utilities generated by the 10 primary studies, including the methods and population used to derive 19 
them. No study asked women to explicitly consider the risk of overdiagnosis when valuing the health 20 
states described.  21 
Utilities informing breast screening policy are restricted in their ability to reflect the full 22 
benefits and harms. Evaluating the true cost-effectiveness of breast cancer screening will remain 23 
problematic, unless the methodological challenges associated with valuing the disutilities of screening 24 
are adequately addressed.    25 
 26 
Keywords: health state utility value, quality of life, QALY, breast cancer, mammography, screening 27 
 28 
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Introduction 29 
Evidence regarding the cost-effectiveness of healthcare technology is increasingly required to inform 30 
the decision on whether to fund and implement new treatment (1). Many decision-making bodies 31 
require interventions to be assessed using cost per quality-adjusted-life-years (QALYs) (2), a single 32 
summary measure combining life expectancy with individuals’ relative preferences for health states in 33 
terms of quality of life (3, 4). Health state utility values (HSUVs) are cardinal measures of preference 34 
rated on a utility scale anchored from dead (0) to perfect health (1). Utilities can be valued directly or 35 
indirectly (5). Direct methods ask individuals to value hypothetical health states, and preferences are 36 
directly measured onto the utility scale using the standard gamble (SG), time-trade off (TTO) or 37 
visual analogue scale (VAS) (6). The TTO and SG elicit individual choices under uncertainty in life 38 
expectancy or risk of death and good health (7), whereas the VAS provides an intermediate valuation 39 
of health on a graduated rating scale (8).  Indirect methods use a generic multi-attribute utility 40 
instrument (MAUI), such as the EuroQol-5 Dimensions (EQ-5D) (9). Current or hypothetical health is 41 
mapped onto a generic health instrument and indirectly valued using tariffs for the generic health 42 
states that have previously been estimated using direct valuation methods from the general population 43 
(10).  44 
 45 
Economic evaluations impact health policy decisions and so the methodological quality of the 46 
parameters used to inform such analyses must be robust (11). Whilst a growing wealth of literature 47 
has explored the importance of the economic approach used, less attention has been given to the 48 
methods and quality of the evidence used to inform HSUVs and thus QALYs (12). It is important that 49 
the methods used to identify, select and appraise utilities are transparent and systematic to reduce 50 
model bias and potential misallocation of resources (13). Several criteria are important for the 51 
selection of relevant HSUVs (14). The first relates to the health states, methods, descriptive system 52 
and population used to elicit the utilities. Where HSUVs have been measured directly, the validity, 53 
reliability and feasibility of the generated values should also be explicitly considered (15). Second, the 54 
duration of impact applied must be measured appropriately for both temporary and chronic health 55 
states associated with the intervention (16). The third relates to the generalisability of the condition, 56 
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severity and population characteristics in the utility study to those in the economic evaluation using 57 
them (2). 58 
 59 
The quality of the HSUVs applied is particularly pertinent in the appraisal of oncological 60 
interventions, where quality of life may have greater influence on QALYs than the modest gains in 61 
life expectancy (17). Many studies have evaluated the cost-effectiveness of breast cancer screening 62 
(18, 19), with those including quality of life in their evaluation reporting fewer net benefits, yet few 63 
have commented on the quality of the utility estimates used to inform them. When deciding on 64 
preferred screening policy it is critical to be able to accurately value the options available to women of 65 
being able to attend routine screening (20). This means valuing all associated benefits and risks 66 
associated with the alternative screening policy in terms of utility (21).  67 
 68 
Screening for breast cancer in women aged 50 to 74 is recommended because of the ability to capture 69 
disease earlier and reduce treatment intensity and disease mortality (22, 23). Decision makers must 70 
value the risk that screening would lead to a woman having necessary (and perhaps less intense) 71 
treatment at an earlier stage than she would have otherwise had, against the risk of the woman having 72 
an unnecessary diagnosis and treatment (24). This valuation is made even more challenging because 73 
there is limited evidence on the rate of progression for many breast tumour types (25). If policy 74 
makers are to interpret cost-effectiveness analyses of mammography screening and balance the 75 
benefits and harms of such interventions appropriately, the utilities used in such evaluations must 76 
reflect the health states and effect on those experiencing the sequalae, including overdiagnosis and 77 
overtreatment (20). 78 
 79 
The challenges associated with valuing health states for breast cancer screening 80 
There are several challenges relating to the identification and assessment of HSUVs for use in the 81 
economic evaluation of breast cancer screening programmes specifically. First, the natural history of 82 
breast cancer is poorly understood (26, 27). Not all valuation methods for deriving utility may account 83 
for the uncertainty in disease progression in the valuation process (28). Second, overdiagnosis and 84 
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overtreatment from screening create a “paradoxical popularity” because individual women may value 85 
unnecessary treatment inappropriately if screening and intervention for benign disease is misconstrued 86 
as life-saving (29). Qualitative evidence suggests that both population and patient understanding of 87 
overdiagnosis is poor (30), with most perceiving the prognosis of pre-cancerous disease equal to that 88 
of an invasive breast cancer (31). Third, the sequelae associated with breast screening last for different 89 
durations (32). The long-term implications of a mastectomy are permanent (33), but the anxiety or 90 
reassurance associated with mammography screening or diagnostic investigation may only be 91 
temporary (34). Temporary health states require modification of conventional valuation methodology 92 
and economic evaluations must consider how both temporary and chronic health states are valued 93 
simultaneously within a single model (35). Fourth, it is unclear whose preferences would be best 94 
placed to assess the benefits and harms of breast screening (36). The National Institute for Healthcare 95 
and Clinical Excellence (NICE) advocate the use of general population preferences in a publicly 96 
funded healthcare system, (2) yet given the complexity involved in valuing screening it may be 97 
difficult for the lay person to quantify using conventional utility instruments. The preferences and 98 
disease characteristics of individual women and breast cancers also vary significantly by demographic 99 
(37) and so the generalisability of the population in the primary and economic studies may influence 100 
the generated QALYs (38). Such challenges may impact utility instruments, therefore an assessment 101 
of the methodology used to overcome these issues is critical in the appraisal of appropriate HSUVs.  102 
 103 
Objectives 104 
The objectives of this study were to critically appraise and assess how economic evaluations have 105 
captured the health states and utilities associated with mammography screening. Primary studies that 106 
have measured HSUVs for relevant health states were also evaluated to examine the quality of the 107 
evidence informing cost-effectiveness studies of breast cancer screening and its sequalae.  108 
 109 
Methods 110 
The review followed the UK Centre for Review and Dissemination (39) guidelines and Preferred 111 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (40). 112 
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 113 
Eligibility Criteria 114 
The systematic review included studies published in English whereby utilities were either used or 115 
elicited for health states relating to mammography screening specifically. Studies were included if 116 
they met the following criteria: the participants were women in the general population at risk of breast 117 
cancer, the intervention (for economic evaluations) was population mammography screening, the 118 
comparator was no screening and the outcomes were cost per QALY (for economic evaluations) or 119 
the measurement of health state utility values associated with breast cancer screening and its sequalae. 120 
Studies were excluded if they were reviews, editorials, interventions to improve screening 121 
participation or breast screening programmes using technologies other than routine mammography 122 
(e.g. ultrasound or magnetic resonance imaging), which are not routinely used for screening the 123 
general population.  124 
 125 
Search strategy  126 
Eleven electronic databases were searched for studies published up to 1 September 2018: MEDLINE, 127 
EMBASE, PsycInfo, CINAHL, Econlit, Social Citation Index, Social Sciences Citation Index, 128 
Cochrane library, NHS Economic Evaluation Database, Database of Abstracts of Reviews and 129 
Effects, and Health Technology Assessment. The reference lists of relevant studies were hand-130 
searched to identify any further relevant studies for inclusion.   131 
 132 
The search strategy was developed using the terms published in other systematic reviews of breast 133 
cancer screening programmes (20, 41) and Cochrane review guidelines (39). Both Medical Subject 134 
Heading and keyword searches were used relating to the term ‘mammography’, ‘breast cancer’, 135 
‘screening’, ‘overdiagnosis’, ‘economic evaluation’ and ‘utility’, with truncation used where 136 
appropriate (see Supplementary File). There was no restriction placed on publication year to ensure all 137 
relevant studies to date were included in the review.   138 
 139 
Study selection  140 
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Information retrieved by the database search was managed via Endnote referencing software (42). A 141 
two-stage process (43) was used to identify relevant studies for inclusion in the final review. In the 142 
first stage, the title and abstract of retrieved studies were checked against the pre-specified eligibility 143 
criteria. Relevant studies or those where a decision could not be made based on the title and abstract 144 
proceeded to the second stage. In stage two, the full text was assessed for relevance and the reference 145 
lists of key articles were hand-searched to identify other potentially relevant studies. Studies citing or 146 
reporting utilities which met the required eligibility criteria were included in the final review. A 147 
second reviewer screened and checked a sub-sample of studies to negate any selection bias (44). 148 
 149 
Data extraction and analysis  150 
An electronic template was used to extract data on the characteristics of the included studies. For each 151 
included study, one reviewer extracted data about the study characteristics, the health states and 152 
utilities reported and the methodology, population, instruments and duration for which utilities were 153 
applied. The data were tabulated and analysed by narrative description as the retrieved HSUVs were 154 
too heterogeneous to usefully combine in a meta-analysis. A formal quality appraisal was not 155 
performed as there is no agreed quality assessment checklist for assessing studies of this nature (11). 156 
However, the methods suggested by Brazier (36) and Papaioannou (11) for the systematic 157 
identification, selection and assessment of HSUVs from the literature were used to assess the validity, 158 
reliability and robustness of the identified utilities to inform the narrative review (28, 45). 159 
 160 
 161 
Results  162 
 163 
The database search retrieved 9,447 studies, of which 3,562 were removed as duplicates. A further 3 164 
studies were identified through hand-searching the reference lists of relevant studies. A flow diagram 165 
of the studies selected or excluded at each stage, with reasons, is provided in Figure 1.   Data were 166 
extracted for the 50 relevant studies included in the narrative review:  40 economic evaluations using 167 
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cost per QALYs and 10 primary studies that measured utilities for health states associated with 168 
mammography screening.   169 
 170 
 171 
Economic evaluations using Cost per QALY 172 
 173 
Table 1 summarises the characteristics of the 40 economic evaluations using QALYs in their analysis 174 
of breast screening programmes. Most evaluated alternative breast screening strategies (46-67), 175 
although five studies (68-72) only presented results using cost per QALY in the sensitivity analysis 176 
because of the uncertainty around published HSUVs for mammography. Seven studies (68, 70, 72-76) 177 
explored the cost-effectiveness of screening elderly women, whereas two studies (77, 78) evaluated 178 
extending the lower age limit of screening. Four studies (71, 79-81) assessed the benefits of risk 179 
stratified mammography screening and one study (82) appraised opportunistic versus organised 180 
mammography screening. The remaining three studies (29, 83, 84) evaluated the benefits and harms 181 
of breast cancer screening but reported QALYs without costs in their main analysis.  182 
 183 
The utilities associated with breast cancer screening are difficult to compare because each study made 184 
different assumptions about the value used, the duration over which they were applied and the 185 
sequalae included in each of the health states. The values used for screening attendance varied 186 
significantly (0.100-0.994) and were applied for a duration of between 2 hours and 7 days. There were 187 
similar issues with heterogeneity between HSUVs for diagnosis (0.100-0.895) and treatment (0.100-188 
0.990). Utilities were applied for between 5 days and 6 months for a positive mammogram and a 189 
duration of one month to the rest of the woman’s life for treatment depending on classification by 190 
intervention or disease stage. The duration of utilities or disutilities when applied in economic models 191 
can be a key driver in influencing results using QALYs (85), yet few studies justified the duration 192 
enforced (29, 80, 81) or considered whether the utilities for temporary health states had used an 193 
appropriate chaining adaptation (86).  194 
 195 
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Most economic evaluations used the same two sources (32, 62) for their utilities, although there was 196 
variation in the actual value used and the generalisability of the population for which they were 197 
applied. The first of these sources by Stout et al. (62) applied tariffs based on assumptions for 198 
screening, diagnosis and treatment of breast cancer by stage at diagnosis to adjust US healthy 199 
population EQ-5D estimates (87). Although the generated utilities were deemed consistent with those 200 
reported in other studies (17, 88), it is not clear how the assumed adjustment for each health state was 201 
determined, and yet nine economic evaluations (29, 47, 49, 63-65, 78, 83, 84) applied this method. 202 
For screening disutility, almost half of the economic evaluations (29, 48, 51, 54, 56, 58, 60, 63, 65, 203 
66, 68, 73, 74, 78, 84) used expert VAS utilities derived from a second study in the Netherlands (32), 204 
but only three economic evaluations (51, 54, 73) considered the generalisability of the expert sample 205 
to the general population in the model to which this was applied. Other economic evaluations made 206 
their own adjustments to local population EQ-5D or SF-6D data (47, 49, 50, 59, 69, 79, 81) or used 207 
HSUVs elicited directly (VAS, TTO, SG) from samples of women with comparable demographics to 208 
try and improve the relevance of the applied utilities to the population in their economic model (52, 209 
73, 77). The remaining evaluations cited utilities from another economic model (53, 67), systematic 210 
review (46) or made their own assumption of an appropriate value (57, 70-72) but did not provide a 211 
detailed critique of how these were derived.   212 
 213 
Sensitivity analyses were used to analyse the uncertainty around HSUVs in the majority of the 40 214 
economic evaluations, with at least half reporting quality of life as having a significant effect on cost-215 
effectiveness results. However, not all economic evaluations included all relevant phases of the 216 
mammography screening pathway in their analysis and therefore implicitly assumed they had no 217 
impact on quality of life. 22 studies (29, 46, 47, 52, 53, 55-59, 64, 67-69, 71, 72, 75, 77, 79-81) did 218 
not integrate the potential reassurance or disutility of screening anxiety and diagnostic follow-up in 219 
their analyses and a further 27 did not explicitly capture the disutility relating to the risk of 220 
overdiagnosis (29, 46, 48, 49, 51-59, 61, 62, 64, 67-71, 73-77). Consequently, no utility loss was 221 
applied to reflect this uncertainty in more than half of the economic evaluations, which may bias 222 
results (QALYs) toward more frequent screening (29, 49, 52, 54, 59). This limitation was justified in 223 
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five studies due to the lack of robust HSUVs for mammography screening. For the 13 studies (47, 50, 224 
60, 63, 65, 66, 78-84) which did attempt to value overdiagnosis in their analysis, an assumption was 225 
made that this was captured in the QALYs across screening strategies by including the temporary 226 
disutility of diagnosis and treatment without a corresponding gain in life years. However, the utilities 227 
applied used sources which had not highlighted that there was a risk the treatment was unnecessary 228 
during the valuation process and therefore is unlikely to fully capture the impact of the risk of 229 
overdiagnosis on quality of life.  230 
 231 
Primary studies 232 
 233 
Ten primary studies (15, 16, 32, 34, 89-94) valued utilities for health states relevant to mammography 234 
screening. A summary of the study characteristics and methodology is shown in Table 2. The studies’ 235 
aims were diverse and measured utilities for a range of relevant health states, including: screening 236 
attendance and anxiety, mammography result (true positive, false positive, true negative and false 237 
negative), diagnostic investigation of a positive mammogram, treatment of a screen detected breast 238 
cancer, breast cancer recurrence and terminal care. The risk of overdiagnosis was not valued 239 
independently or explicitly captured within the descriptions of treatment health states in any of the 240 
primary studies of breast screening.  241 
 242 
Methodology 243 
The main method for valuing health states include direct and indirect empirical measurement or 244 
expert opinion (95). Multiple approaches were taken to elicit utilities for breast screening health states 245 
identified by this review, with more than four different valuation techniques reported within the 246 
primary studies. These four primary approaches included the VAS (96), which was anchored from 247 
worst to best imaginable health, standard gamble which compared the health state against a gamble of 248 
death and perfect health (97), time trade-off which trades years lived in full health against living 249 
longer in the health state being valued (98) and EQ-5D which asked trial participants to report their 250 
own or hypothetical health on a generic scale and applied general population tariffs to estimate final 251 
10 
 
utility scores (99). More than one technique was used to value screening health states in six studies 252 
(15, 16, 34, 90, 93, 94), whilst the remainder used a single technique (32, 89, 91, 92). The standard 253 
gamble, initially presented by Neumann and Morgenstern (100) in (101) is the gold standard method 254 
for valuing conditions of uncertainty (102), yet only two studies (90, 93) used this technique to 255 
capture the potential benefit and risks associated with screening. An alternative choice-based method 256 
(TTO) was justified by five studies to reduce cognitive burden associated with the standard gamble 257 
(15, 16, 90-92). De Haes et al. (32) did not use a choice-based method but mapped visual analogue 258 
scale scores into utilities using a power function (VAS): TTO = 1-( 1-VAS)^1.82. (103), although 259 
there are reported issues with the reliability of conversion formulas (104). A combination of both 260 
direct and indirect methods was used by the remaining studies (34, 94) using tariffs from the US (87) 261 
and Dutch general population (105) for the EQ-5D descriptive instrument before and after screening. 262 
The Short Form-36 questionnaire was also used by Rijnsburger (94), but the values were never 263 
mapped into SF-6D utilities (106). Only half of the studies considered whether the chosen method 264 
was appropriate for overcoming the methodological challenges associated with screening health states 265 
(15, 16, 32, 91, 92).  266 
 267 
Duration 268 
Traditional methods such as the standard gamble, TTO and VAS are targeted towards chronic health 269 
states (5, 6, 102). For valuing temporary health states, a two-stage technique known as ‘cascading’ or 270 
‘chaining’ is recommended and can be applied to modify the traditional TTO or SG approach (107). 271 
For chaining, the worst temporary health state is known as the anchor health-state because it is used as 272 
the lower anchor instead of dead (35). The anchor state is subsequently valued against full health and 273 
dead to realign values onto the traditional utility scale (6). Only two studies (15, 16) used a chaining 274 
adaptation of the conventional TTO to appropriately value temporary health states for screening 275 
attendance and diagnostic investigation.  276 
 277 
A combination of direct and indirect assumptions (108) were used to specify duration in the remaining 278 
studies. Four studies (90-93) specified a single duration of impact for both temporary and chronic 279 
11 
 
health states and applied the same method (TTO or SG) to ensure consistency. The same technique 280 
(VAS) was used in two studies (32, 89) to specify the time within the vignettes, although the durations 281 
applied varied depending on the timeframe assumed. Other studies (34, 94) did not specify the health 282 
state duration per se but indirectly measured utility at discrete time points during the screening 283 
process. However, due to variation in follow-up time some women were aware of their results a priori 284 
which may have inadvertently biased results.   285 
 286 
Descriptive system 287 
The validity of the health state and utility elicited is dependent on the accuracy of the vignette and 288 
should be informed by a thorough review of the literature or input from those well acquainted with the 289 
condition (104, 109). HSUVs were generated using health state descriptions in eight (80%) of the 290 
primary studies (15, 16, 32, 89-93). Although the vignettes in all eight studies were informed by 291 
clinical guidelines and expert input, only five studies (15, 16, 32, 89, 92) validated the clinical 292 
scenarios through patient piloting or focus group discussion. Similarly, the framing and labelling of 293 
health descriptions can systematically bias choices and perceived quality of life due to the negative 294 
connotations associated with cancer and dying (110, 111), yet only two studies (91, 92) explicitly 295 
considered the impact of this on their results. The remaining two studies (34, 94) did not use vignettes 296 
but indirectly measured the disutility associated with screening by asking women enrolled in a clinical 297 
trial of tailored mammography to value their own health ex-ante and ex-post screening using validated 298 
health instruments (EQ-5D). Interestingly, both studies commented on the limitations of the 299 
sensitivity of the EQ-5D domains in capturing changes in utility for the short-term duration of 300 
screening.   301 
 302 
No primary study explicitly considered the impact of the risk of overdiagnosis or unnecessary 303 
treatment in any of the health states described. Only Gerard (91) and Hall (92) introduced the notion 304 
of dying of causes other than breast cancer in their vignettes, although they did not explicitly include 305 
the risk of unnecessary follow up and treatment. Kim et al. (93) explicitly included risk in their health 306 
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state descriptions of surgery and radiotherapy but only provided estimates for recurrence and survival, 307 
assuming all treatment was necessary for non-invasive disease. 308 
 309 
Population 310 
Health states relevant to breast screening can be valued by three populations groups; the general 311 
population, patients and clinical experts (36). Seven (15, 16, 34, 89, 91, 93, 94) of the ten primary 312 
studies used general population values, which are preferred by most publicly funded healthcare 313 
departments (2, 99), although there was some selection bias toward women of breast screening age. 314 
One study (92) collected a mixed sample of public and patient preferences and reported significant 315 
differences between the HSUVs measured by those with and without experience of breast cancer. 316 
Patient preferences are typically higher than those elicited from the public due to adaptation to the 317 
condition or a feeling of necessary intervention (36, 112), but Hall (92) justified their approach as 318 
they felt patients were best placed to value the complex side-effects associated with breast surgery. 319 
The remaining two studies (32, 90) used an expert sample to overcome the cognitive difficulties 320 
experienced in their feasibility piloting of TTO health states. 321 
 322 
Quality assessment 323 
Most studies did not explicitly comment on the quality of the reported HSUVs in terms of the validity, 324 
reliability and feasibility of the methods used. Among the four studies (15, 16, 32, 91) that reported on 325 
reliability, four assessed ranking order and only one (15) tested test-retest consistency. None of the 326 
primary studies commented on the time taken to complete the task, although this is routinely 327 
recommended for appraising participant comprehensibility (28, 97). At least half of the authors 328 
commented on comprehensibility issues relating to the SG and TTO techniques, although only one 329 
study (15) provided quantitative evidence to measure the reported cognitive burden using a Likert 330 
scale. Whilst most studies justified the VAS based on task acceptability, only three studies (15, 16, 331 
32) considered the theoretical validity of this approach in capturing the temporary or uncertain 332 
benefits and risks associated with breast screening specifically.  333 
 334 
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Discussion 335 
 336 
Principal findings 337 
Population based mammography screening for breast cancer is a major public health investment and 338 
significant time investment for women and therefore warrants rigorous scrutiny (20). This systematic 339 
review provides the first synthesis of economic measures and health states used to value 340 
mammography screening, explicitly including overdiagnosis, and summarises the evidence base 341 
informing the population screening debate. The identified evaluations found that quality of life had a 342 
significant effect on cost-effectiveness results in sensitivity analyses . Determining whether the 343 
associated benefits and harms have been captured appropriately is therefore not only of clinical 344 
importance, but may impact how screening policy is determined or overdiagnosis is conceptualised 345 
(20).  346 
 347 
Deciding how   breast screening utilities should be captured is fraught with challenges (24, 41). There 348 
is no consensus on the most appropriate economic measure and population to use when valuing 349 
outcomes in   cancer screening programmes. Half of the identified studies in this review used the 350 
same two sources to value quality of life (32, 62), but the remainder used values that were based on 351 
assumption, used out of context or were not methodologically sound. Unlike prostate and cervical 352 
cancer, the natural history of in situ breast disease  is not well understood (26), yet the way in which 353 
the utilities were assigned to represent the associated health states for screening and its sequalae were 354 
not described in detail in any of the studies. Balancing the availability and quality of published 355 
HSUVs to inform economic evaluations can be problematic where primary evidence is limited (7), but 356 
it is imperative that such limitations are made explicit so that decision makers may consider the 357 
implications upon cost-effectiveness results (113).   358 
 359 
The heterogeneity in utility values raises the question of what economic measure should be used, or 360 
whether health related quality of life is suitable for measuring outcomes associated with screening and 361 
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overdiagnosis. The commonest approach used in the empirical studies was the VAS, despite this 362 
technique being considered methodologically inferior to other choice-based techniques (114, 115). 363 
Ideally, the measure chosen should reflect the underlying decision within the valuation process, in line 364 
with traditional axioms of utility theory (116). When trading length of life against quality, TTO is 365 
more appropriate (86), whereas in a situation in which there is also risk (such as screening and 366 
treatment uncertainty), the standard gamble may be more suitable (97). A systematic review of 367 
metastatic breast cancer utilities (41) found that the SG was the most frequently used technique for 368 
capturing uncertainty in survival and  preferred for valuing risk-based utility (112), although there are 369 
concerns it may inappropriately conflate health with risk aversion (124).  Conversely, preference-370 
based instruments (EQ-5D) are considered the method of choice by NICE (117), but it is unclear 371 
whether an indirect approach would be sufficiently sensitive to detect minor changes in utility (34) or 372 
reflect the true risks involved, unless respondents are adequately informed about the benefits and 373 
harms during the valuation process or vignette. With the majority of identified studies using HSUVs 374 
based on author assumption, new empirical evidence to reliably inform such analyses is clearly 375 
necessary.  376 
 377 
The clinical outcomes associated with breast cancer screening programmes are widely contested, yet 378 
the benefits and harms of mammography are inadequately appraised in the economic literature 379 
informing the debate. Few studies identified by this review integrated all relevant phases of care 380 
associated with breast cancer screening into the assessment of quality of life, and the values used were 381 
limited in their ability to truly capture the disutility Thirteen studies included overdiagnosis in their 382 
evaluation but applied the same utilities for diagnosis and treatment as a non-overdiagnosed 383 
cancer(118-120), even if the costs and quality of life losses were ultimately not necessary or entirely 384 
representative. Estimates of screen detected overdiagnosis vary significantly from 0 to 54% (23, 27). 385 
Whilst several economic evaluations cite the lack of published utilities as a justification for not 386 
including screening or overdiagnosis in their analysis (29, 49, 52, 54), ignoring this harm may 387 
inadvertently lead to inappropriate advice to women, decisions on the value of screening programmes 388 
and potential misallocation of resources. Similarly, none of the primary studies explicitly considered 389 
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the impact of unnecessary treatment in their vignettes. The inclusion of overdiagnosis in qualitative 390 
descriptions has been shown to change general population preferences toward more conservative 391 
management or surveillance strategies(121, 122). The limitations of the economic measures and 392 
health states outlined in this review (123) raises concerns about information asymmetry, and whether 393 
women can make an informed decision about screening without information on the full benefits and 394 
risks. Any potential advantages and risks should be explicitly listed within the descriptions of relevant 395 
health states. These findings are not limited to breast cancer; appraising the impact of unnecessary 396 
treatment may be relevant in other public interventions such as prostate cancer (120), cervical 397 
screening (124) or the management of cardiovascular disease, where treatments reduce the risk of 398 
future morbidity and mortality but have side-effects (125). Indeed, a number of cancer screening 399 
initiatives have reported varying outcomes when different sets of utilities are assumed (119, 126). 400 
 401 
The literature is similarly heterogeneous in the duration and methods used to apply HSUVs. A 402 
difficulty in valuing screening interventions is that the process encompasses both temporary and 403 
chronic health states (16). The intensity and duration of the utilities associated with screening (15) and 404 
diagnostic anxiety (127, 128) vary significantly to the long-term sequelae associated with treatment 405 
(129), depending on whether this is classified by intervention or disease stage. There is ongoing 406 
debate about how best to overcome such issues (130), including the adaptation of conventional direct 407 
approaches (112, 131) or clinical guidelines on the duration of impact for each of the health states 408 
(20). Whether such adjustments are practical for screening interventions is debated and there are 409 
limitations of QALYs in interventions such as breast screening which may only have a transient 410 
impact on utility yet may be highly valued. Thorough sensitivity analysis of the durations applied to 411 
QALYs should be undertaken in any economic evaluation of population mammography screening to 412 
ascertain the effect of key drivers on cost-effectiveness (35, 38).  413 
 414 
Two systematic reviews (19, 132) have previously explored the outcomes of economic evaluations 415 
relating to breast screening programmes. Schiller-Fruhwirth et al. (19) reported on the lack of breast 416 
screening specific utilities and insufficient reporting of validation in their review of economic models. 417 
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A second review (132) reported similar findings relating to a paucity of methodologically appropriate 418 
utilities relevant to mammography screening. Other systematic reviews (17, 41) of economic 419 
outcomes in the broader breast cancer literature have been equally unable to combine screening values 420 
in meta-analyses due to insufficient numbers and inconsistencies in the approach and population used 421 
to derive  them.  422 
 423 
Strengths and limitations 424 
The value of this review is that it provides a critical appraisal of the HSUVs used in economic 425 
evaluations of breast screening programmes, alongside a wider appreciation of the methodological 426 
issues and challenges associated with the empirical valuation of mammography and its sequelae. It 427 
offers new insight into the methodological issues informing the screening and overdiagnosis debate, 428 
and recommendations on where to direct future research to improve the appraisal of population 429 
screening services. Nonetheless, this review also has limitations. Some studies were not explicit in 430 
stating that the condition under study was relevant to mammography screening. Therefore, a 431 
subjective judgment had to be made by the reviewers about the health states measured and their 432 
relevance for inclusion. Second, the review only included studies published in English and may have 433 
excluded relevant HSUVs in other publications. Finally, a summary statistic for the health states 434 
associated with mammography screening could not be determined due to the heterogeneity between 435 
studies and the methods used to derive reported HSUVs.  436 
 437 
Implications 438 
Utilities informing breast screening policy are restricted in their ability to reflect the full benefits and 439 
harms. Primary health state estimation, incorporating the potential benefits and risks  in the valuation 440 
process, should be pursued to provide methodologically robust empirical data for the economic 441 
appraisal of mammography screening policy. To exclude such harm from the evaluation process is 442 
negligent. . As screening evolves in line with technological advancements and improvements in 443 
genetic understanding (future risk), quality of life values should also be adjusted. Similarly, as the 444 
identification of low risk disease from screening becomes more prevalent (25), it is likely that more 445 
17 
 
personalised, risk-stratified utilities for active monitoring strategies will be required in breast cancer 446 
screening models.  447 
 448 
Recommendations for future research 449 
The economic evaluation of mammography screening remains problematic due to uncertainties in the 450 
natural history of the disease, duration of sequalae and risk of potential unnecessary treatment. The 451 
following methodological recommendations are highlighted for researchers planning economic 452 
evaluations of population breast cancer screening: 453 
 Economic evaluations should explicitly include all relevant utilities and disutilities associated 454 
with mammography screening and its sequelae. Overdiagnosis should be explicitly captured 455 
in the evaluation of population screening policy, alongside extensive uncertainty analysis 456 
where there is debate on the extent of unnecessary treatment. 457 
 New empirical evidence based on adequately informed utility data is needed to inform breast 458 
cancer screening decisions. The findings suggest the standard gamble and EQ-5D as the most 459 
appropriate economic measures to value screening health states, but vignettes should 460 
explicitly describe the advantages and risks of screening during the valuation process. 461 
 Groups at high or low risk for breast cancer should be considered in sub-group analysis, and 462 
quality of life values risk-stratified accordingly. It is likely that the management and 463 
prognosis for ductal carcinoma in situ will have markedly different implications than the 464 
disutilities associated with high risk, invasive disease. 465 
 Consistency in the duration for which the penalties are applied to screening, diagnosis and 466 
treatment related health states should be standardised by a panel of experts, clinicians and 467 
patients to prevent study heterogeneity driving cost-effectiveness results.  468 
 Breast cancer screening evaluations assume perfect compliance with treatment which may not 469 
be reflective of clinical practice. The utility of active surveillance or non-invasive 470 
management, included in other population cancer screening evaluations, may be adopted by 471 
some women with low risk disease and should be considered in the breast cancer setting. 472 
18 
 
 473 
Conclusion  474 
Breast cancer screening programmes are deemed cost-effective for women aged 50-74 in the general 475 
population. Nonetheless, the evidence informing breast cancer screening policy have several 476 
limitations that must be addressed to determine what would be the most cost-effective approach. This 477 
review highlights the methodological challenges associated with valuing the utilities and disutilities 478 
associated with breast cancer screening, and suggests economic measures are unlikely to adequately 479 
capture the outcomes of screening in terms of quality of life.  480 
There is no single recommended approach for valuing the health states associated with breast 481 
cancer screening and its sequalae, but women should be properly informed about the benefits and 482 
risks during the valuation process or vignettes.  Overdiagnosis is not appropriately accounted for in 483 
the appraisal of mammography screening and undervaluation may lead to inappropriate decisions on 484 
the value of screening programmes. The measurement of health state utility values derived from 485 
adequately informed individuals, as well as sub-group analysis by risk group, is necessary if the 486 
debate on population screening programmes is to be adequately addressed. 487 
 488 
 489 
 490 
 491 
 492 
 493 
 494 
 495 
 496 
 497 
 498 
 499 
 500 
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Figures and Tables 854 
Figure 1: A PRISMA flow chart of studies included and excluded at each stage 855 
856 
Studies identified through database 
searching  
(n = 9,447) 
Additional studies identified 
through other sources  
(n = 3) 
Studies after duplicates 
removed (n = 5,888) 
Stage I: Studies screened 
(n = 5,888) 
Studies excluded based on 
title & abstract (n = 5,733) 
Stage II: Full-text articles 
assessed for eligibility  
(n = 155) 
Full-text articles excluded 
(n = 105): 
 
Abstract only: (n = 22) 
No HSUVs: (n = 49) 
Review: (n = 14) 
No screening HSUV: (n=1) 
BSP with other technology: 
(n = 15) 
Methodology study: (n = 3) 
Foreign language: (n = 1) 
Studies included in the 
final review (n =50) 
 
-  40 economic evaluations 
-  10 primary studies with 
health state utility values 
Studies excluded as 
duplicates (n = 3,562) 
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Table 1: Characteristics of the 40 economic evaluations  
Lead 
Author 
 
Study objective 
 
Country; Population; 
Study type 
Health states included 
 
Method used by 
cited HSUVs  
Information presented about HSUVs HSUVs in study Duration Cited 
sources 
for 
HSUVs 
Ahern  
(46) 
 
Assess the cost-effectiveness of 
mammography screening and breast 
examination  
USA; Women aged 40-
79; 10 MM strategies (1-
2y +/- CBE); MSM 
Treatment (intervention)  VAS  
 
Utilities from another model and systematic 
review (expert VAS transformed to SG using 
SG=1-(1-VAS)2.29  
0.590-1.000 
 
6 months, 1 
year, lifelong 
(17, 133) 
Arrospide  
(47) 
Retrospective economic evaluation of 
Basque BSP 
Spain; Women aged 50-
69; 2y MM, MSM 
Diagnosis 
Treatment (disease stage) 
EQ-5D 
assumption 
Applied assumptions from another model: tariff 
for the disutility of breast cancer applied to 
healthy population EQ-5D data (Spain). 
0.338-0.824 1 year/ life 
expectancy  
 
 
(62) 
Barratt (73) Assess the cost-effectiveness of 
extending BSP for women over 70  
Australia; Women aged 
over 70, 2y MM, MSM  
Screening 
Diagnosis 
Treatment (intervention) 
VAS 
 
 
Extrapolated the QALYs from another model 
which used expert VAS (systematic review). 
0.288-0.994 Unclear  (32, 74) 
Beemsterboe
r 
(48) 
Economic evaluation of different 
screening strategies in Germany  
Germany; Women aged 
50-69, 2y MM, MSM 
Screening 
Diagnosis 
Treatment (intervention) 
VAS  
 
 
Expert VAS utilities and durations 
(transformed to TTO) 
0.288-0.994 1 week-lifelong (32) 
Boer 
(74)  
Economic evaluation of extending the 
upper age limit of BSP 
Netherlands; Women 
aged 50-69 and >70; 2y 
MM; MSM 
Screening 
Diagnosis 
Treatment (intervention) 
VAS  
 
 
Expert VAS utilities and durations 
(transformed to TTO) 
0.288-0.994 1 week-lifelong (32) 
Carles  
(49) 
Economic evaluation of breast 
screening strategies in Catalonia 
Spain; Women aged 50-
79; 1-2y MM, 
Probabilistic model 
Screening 
Diagnosis 
Treatment (disease stage) 
EQ-5D 
assumption  
Used the assumptions for duration and loss 
from healthy population EQ-5D in another 
model (US) 
0.657-0.994 7 days-lifelong (62) 
Christensen  
(50) 
Evaluate the cost-effectiveness of 
mammography screening in 
Greenland. 
Greenland; Women aged 
50-69; 2y MM; CEA 
Screening 
Diagnosis 
Treatment (intervention) 
Systematic 
review, 
assumption 
Population QoL (Greenland) adjusted using 
values from a systematic review. Methods not 
reported. 
0.480-0.810 6 months (41) 
De Gelder 
(82) 
Economic evaluation of opportunistic 
and organised population 
mammography screening  
Switzerland; Women 
aged 50-69; 2y MM, 
MSM 
Screening 
Diagnosis 
Treatment (intervention) 
VAS  
 
Expert VAS utilities and durations 
(transformed to TTO) used in another model 
 
0.288-0.994 1 week- lifelong (32, 51)  
De Koning 
(51) 
Evaluate the cost-effectiveness of 
different BSP strategies 
Netherlands; Women 
aged 40-75; 5 variants 
1.3-3y MM, MSM 
Screening 
Diagnosis 
Treatment (intervention) 
VAS  
 
 
HSUVs and durations based on 27 experts 
VAS (transformed to TTO) 
0.289-0.994 1 week-lifelong (32) 
Forrest (52) Cost-effectiveness of implementing a 
national BSP in the UK. 
UK; Women aged 50-65; 
3y MM; CUA 
Treatment (intervention) Rosser scale Rosser ratio rating scale values used for the 
disutility of surgery  
0.920 Lifelong (134) 
Haghighat 
(53) 
Economic evaluation of 
mammography screening in Iran 
Iran; Women aged 40-70, 
3y MM, Markov model 
Treatment (disease stage) Assumption Used the assumptions in another economic 
model of BSP 
0.300-0.950 Unclear (67) 
Hakama 
(54) 
Economic evaluation of Nordic breast 
screening strategies. 
Nordic region; Women 
aged 50-69, CUA 
Screening 
Diagnosis 
Treatment (intervention) 
 
VAS  
 
 
Expert VAS utilities and durations 
(transformed to TTO) 
0.288-0.994 1 week-lifelong (32) 
IMS Health 
(55) 
Economic evaluation of BSP in 
Australia  
Australia; strategies for 
women aged 40-79, 2y 
MM, MSM 
Treatment (disease stage) VAS Expert VAS ratings, authors adjusted 
weighting and duration using local treatment 
data 
0.774-0.864 Unclear  
 
(51) 
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Kerlikowske  
(68) 
Economic evaluation of 
mammography screening in elderly 
women. 
USA; Women aged 65-
79; 2y MM, Markov 
model 
Treatment (disease stage) Assumption Authors made assumptions of plausible 
estimates based on published HSUVs 
(TTO/VAS). 
0.300-0.900 Lifelong (32, 92) 
Madan (69) Cost-effectiveness of extending the 
lower age limit of BSP 
UK; Women 47-49 years; 
3y MM; MSM 
Diagnosis EQ-5D 
Assumption 
Baseline UK healthy general population EQ-
5D scores adjusted by assumption in sensitivity 
analysis 
Not reported Unclear (10) 
Mandelblatt  
(70) 
Evaluate the cost-effectiveness of 
BSP in elderly women with and 
without comorbid disease 
USA; Women aged 65-85 
years; 1-2y MM; Decision 
model 
Screening 
Diagnosis 
Treatment (disease stage) 
Assumption Assumption of plausible HSUVs based on 
expert VAS in the literature for similar health 
states  
0.100-0.900 5 days, 30 days, 
life expectance   
 
(32) 
Mandelblatt 
(71) 
Economic evaluation of targeted 
mammography screening in African 
American women 
USA; African American 
women aged ≥40,; 1-2y 
MM; MSM 
Treatment (disease stage) Assumption Assumption of HSUVs by disease stage, no 
description of how values were determined is 
provided.  
0.500-1.000 Unclear No cited 
source 
Mandelblatt  
(72) 
Evaluate the cost-effectiveness of a 
BSP in older women 
USA; Women aged 50+; 
2y MM; MSM 
Treatment (disease stage) Assumption Assumption of HSUVs by disease stage, no 
description of how values were determined is 
provided.  
0.550-0.950 1 year No cited 
source 
Mandelblatt 
(83) 
Partial evaluation of mammography 
strategies considering screening and 
treatment advances 
USA; Women aged 40-
74; 1-2y MM; MSM 
Screening 
Diagnosis 
Treatment (disease stage) 
EQ-5D 
Assumption, 
VAS  
Expert VAS values (screening and diagnosis) 
and assumptions from another model 
(treatment) for US population EQ-5D tariffs 
0.354-0.856 1 weeks, 5 
weeks, 2 years 
(32, 62) 
Messecar 
(75) 
Economic evaluation of BSP for older 
women with and without cognitive 
impairment 
USA; Women aged 75-
85y; 2y MM; Decision 
model 
Treatment (disease stage)  TTO Used general population TTO preferences for 
treatment  
0.260-0.800 Lifelong (91) 
 
Mittmann 
(56) 
 
Updated cost-effectiveness of BSP in 
Canada. 
Canada; Women aged 40-
74; 1-3y MM; MSM  
Screening 
Diagnosis  
EQ-5D 
Assumption, 
VAS  
Expert VAS values (screening and diagnosis) 
and assumptions from another model 
(treatment) for US population EQ-5D tariffs  
0.895-0.994 1 week, 5 weeks, 
2 years 
(32) 
Morton (57) Economic analysis of the BSP in the 
UK 
UK; Women aged 50-70; 
3y MM; CUA 
Screening 
Treatment (intervention) 
Assumption Used QALYs from another economic model of 
the UK BSP 
Not reported Unclear (29, 69) 
Pashayan 
(79) 
Cost-effectiveness or risk-stratified 
screening for breast cancer 
UK; Women aged 50-69; 
3y MM (risk); Lifetable 
Treatment (intervention) EQ-5D 
Assumption 
Used adjusted population EQ-5D utilities from 
another economic model (systematic review) 
Not reported 1 year, lifelong (41, 59, 
135) 
Pataky (58) Cost-effectiveness of population BSP 
by age & frequency 
Canada; Women aged 40-
74; 1-2y MM; MSM 
Diagnosis, Treatment 
(disease stage) 
VAS, SG Systematic review (expert and population VAS 
to SG) 
0.389-1.000 2 weeks- 
lifelong 
(17, 32, 
89, 131) 
Pharoah (59) Economic evaluation of the National 
Health Service BSP 
UK; Women aged 50-70; 
3y MM; Life-table 
Treatment (intervention) EQ-5D 
Assumption 
UK general population EQ-5D adjusted by a 
0.9 relative reduction  
Not reported Lifelong (41, 135) 
Rafia (76) Cost-effectiveness of extending the 
upper age limit of the UK BSP. 
UK; Women aged 50-90; 
3y MM; MSM 
Screening 
Diagnosis 
Treatment (disease stage) 
EQ-5D 
Assumption 
modified by 
VAS, SG 
Expert VAS, population SG and expert opinion 
used to adjust baseline UK population EQ-5D 
0.360-0.910 2 hours, 3 
weeks, 1-3 
years, lifetime 
(10, 89, 
94) 
 
 
Raftery  
(29) 
Assess the benefit and harms of the 
UK BSP (partial evaluation) 
UK; Women aged 50-70; 
3y MM, life-table 
Diagnosis 
Treatment (intervention) 
Assumption Systematic review, other models (expert VAS, 
population EQ-5D) 
Not reported 0.2 years-
Lifelong  
(32, 62) 
(41) 
Rojnik (60) Economic evaluation of alternative 
breast screening strategies in Slovenia  
Slovenia; Women aged 
40-80 years; 1-3y MM; 
MSM 
 
Screening 
Diagnosis 
Treatment (intervention) 
VAS, SG Expert VAS and SG utilities (oncology nurses), 
literature review 
0.515-0.994 1 month-lifelong (32) 
Salzmann 
(77) 
Cost-effectiveness of extending 
mammography screening to women 
aged 40 to 49 years. 
USA; Women aged 40-49 
years and 50-69 years; 
1.5-2y MM, Markov 
model 
Treatment (disease stage) TTO Australian patient TTO utilities in sensitivity 
analysis 
0.300-0.800 Unclear (92) 
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Sankatsing 
(78) 
Cost-effectiveness of mammography 
screening before the age of 50. 
Netherlands; Women 
aged 40-74 years; 2y 
MM; MSM 
Screening 
Diagnosis 
Treatment (disease stage) 
EQ-5D, 
Assumption  
VAS  
Expert VAS utilities (screening, diagnosis) 
Decrements in US healthy general population 
EQ-5D (treatment) from another model.  
Unclear  1 week, lifelong (32, 62)  
 
Schousboe 
(80) 
Cost-effectiveness of mammography 
screening by risk factors. 
USA; Women aged 40-
79; 1-2y MM, MSM 
Treatment (disease stage) EQ-5D  Swedish breast cancer patient EQ-5D applied 
to Swedish general female population EQ-5D  
0.620-1.000 5 days- lifelong (136) 
Souza (61) Economic evaluation of implementing 
a national BSP in Brazil  
Brazil; Women aged 40-
69; 1-2y MM; MSM 
Diagnosis 
Treatment (disease stage 
and intervention) 
SF-6D 
assumption 
Author assumption of plausible estimate for 
false positive MM. HSUVs were estimated 
based on patient SF-6D scores (Brazil) 
0.686-0.800 2 months- 
lifelong 
(137, 138) 
Stout (62) Economic evaluation comparing 
alternative screening strategies.  
USA; Women aged 40-
80; 1-5y MM; DESM 
Screening 
Diagnosis 
Treatment (disease stage) 
EQ-5D 
assumption 
Age-sex specific EQ-5D for healthy women 
(US) adjusted for negative effects of breast 
cancer diagnosis and treatment.  
0.354-0.856 
 
 
1 week- lifelong (62) 
Stout (63) Assess the benefit, harms and costs of 
digital mammography screening  
USA; Women aged 40-
74; 1-2y MM; MSM 
Screening 
Diagnosis 
Treatment (disease stage) 
EQ-5D 
assumption,  
VAS  
Population EQ-5D (US) adjusted using 
assumptions from another model. Expert VAS 
utilities included in sensitivity analysis. 
0.354-0.586 
 
1 week-lifelong (32, 62) 
 
Tosteson 
(64) 
Evaluate the cost-effectiveness of 
digital mammography screening 
USA; Women aged ≥ 
40;1y MM; MSM 
 
Treatment (disease stage) 
 
 
EQ-5D 
assumptions 
Applied the duration and weighting 
assumptions from another economic model of 
BSP to healthy population EQ-5D data (USA) 
0.430-0.860 Unclear (62) 
Trentham-
Dietz (65) 
Economic evaluation of tailored 
mammography screening for women 
over 50 years  
USA; Women aged 50-
74; 1-3y MM (risk); 
MSM 
Screening 
Diagnosis 
Treatment (disease stage) 
EQ-5D 
assumption, VAS 
 
Expert VAS (screening and diagnosis). US 
population EQ-5D (treatment) adjusted using 
assumptions from another model  
Unclear 1 week-lifelong 
 
(32, 62) 
 
Van Luijit 
(2017) (80) 
Economic evaluation of the 
Norwegian BSP 
Norway; Women aged 
50-69; 2y MM; MSM 
Screening 
Diagnosis 
Treatment (disease stage) 
VAS Expert VAS utilities (transformed to TTO) 
from the literature 
0.288-0.994 
 
1 week-lifelong (32) 
Van 
Ravesteyn 
(84) 
Assess the benefits and harms of 
mammography after age 74 years 
(partial evaluation) 
USA; Women aged 50-
94; 2y MM; MSM 
Screening 
Diagnosis 
Treatment (disease stage) 
EQ-5D 
assumption, 
VAS  
Expert VAS for (screening and diagnosis). US 
population EQ-5D assumptions adopted from 
another economic model. 
0.600-0.994 1 week, 5 weeks, 
2 years, life 
expectancy  
(32, 62) 
Vilaprinyo 
(81) 
Cost-effectiveness of risk-based breast 
screening strategies for breast cancer 
Spain; Women aged 40-
74; 1-5y MM, 
Probabilistic model 
Diagnosis 
Treatment (disease stage) 
EQ-5D Patient EQ-5D (Sweden) for treatment 
extrapolated using the methods from another 
model. 
0.655-0.859 2 months-5 years (80, 136) 
Wong (67) Economic evaluation of biennial 
mammography screening in Hong 
Kong. 
China; Women aged 40-
79; 2y MM, Markov 
model 
 
Treatment (disease stage) Assumption  HSUVs from another economic model (but 
values do not match those cited)   
0.300-0.950 Lifelong (71) 
 
 
Legend  
BSP: breast screening programme, EQ-5D: Euroqol-5D, HSUV: health state utility value, LYG: life years gained, MM: mammogram, MSM: microsimulation 
model, QALY: quality adjusted life year, QoL: quality of life, , TTO: Time trade off, SG: standard gamble, VAS: visual analogue scale  
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Table 2: Characteristics of the 10 primary studies which had elicited HSUVs  
Author; 
Country 
Study aim  Participants Health states valued  Utility range Duration range Technique  Further information methods 
 
Bonomi 
USA 
(89) 
Obtain QoL values for 
mammography screening 
and breast cancer treatment 
131 women sampled from a 
population breast screening 
programme (aged 50-79) 
Screening attendance Screening result 
(FP, TN) 
Diagnostic mammogram 
Treatment (intervention)  
Disease free at 1 year 
Recurrence at 1 year 
Terminal care 
0.804 
0.457-0.891 
0.553 
0.397-0.530 
0.768 
0.330 
0.358 
2 hours 
2 weeks 
2 weeks  
4 months-5 years 
Lifelong 
4 months 
3 months 
VAS 
 
14 vignettes via in-person or telephone 
interview.  
VAS anchored death-perfect health 
Chie 
Taiwan 
(90) 
Utility in different clinical 
phases of breast cancer. 
21 clinical and public health 
experts  
 
Screening attendance  
Diagnosis 
Initial treatment (intervention)  
Post-treatment (intervention) 
Recurrence at 1 year 
Terminal care 
0.900-1.000 
0.700-0.900 
0.500-0.800 
0.600-0.800 
0.250-0.300 
0.100-0.150 
20 years for all VAS, TTO  
SG 
17 vignettes via face-to-face interview (visual 
aids).  
VAS anchored death-perfect health. 
De Haes  
Netherlands 
(32) 
 
Elicit utilities for use in an 
economic model of BSP 
27 clinical and public health 
experts 
 
 
 
Screening attendance  
Diagnosis 
Initial treatment (intervention)  
Post-treatment (intervention) 
Disease free >1 year 
Terminal care 
0.994 
0.895 
0.717-0.820 
0.844-0.914 
0.947-0.960 
0.288 
1 week 
5 weeks 
2 months-2 years 
10 months 
Lifelong 
1 month 
VAS 15 vignettes via face-to-face interview.  
VAS anchored worst-best imaginable health. 
VAS scores transformed to TTO using the 
formula: TTO=1-(1-VAS) ^1.82  
Gerard 
Australia 
(91) 
Explore framing and 
labelling effects on breast 
cancer values. 
180 women from the local 
general population (aged 45-
69) 
 
Treatment (intervention) of screen 
detected breast cancer with and without 
breast cancer death 
0.150-0.750 10-30 years (age 
dependent)  
TTO 9 different presentations of two breast cancer 
vignettes (varied cancer terminology and 
pronoun). 
Gerard  
UK 
(15) 
Determine the feasibility 
of mapping EQ-5D to TTO 
for validating breast cancer 
descriptions. 
440 women from the general 
population eligible for breast 
screening (aged 40-64) 
True negative  
False positive 
True negative  
False positive  
 
0.910-0.940 
0.210-0.790 
0.480-0.660 
0.450-0.660 
12 months 
 
Lifelong 
TTO (chain) 
EQ-5D 
Two-stage chaining used to adjust temporary 
health states onto death-full health scale.  
EQ-5D mapped onto TTO using 3/5 dimensions.  
Hall  
Australia 
(92)  
 
Derive utilities for use in 
an economic evaluation of 
BSP in Australia.  
44 women from the general 
population and 60 breast 
cancer patients (aged 45-69) 
Treatment (intervention) of a screen 
detected breast cancer 
0.270-0.800 10-30 years (age 
dependent) 
TTO  6 vignettes via face-to-face interview  
Johnston; UK 
(16) 
Derive QoL values for key 
breast screening outcomes 
440 women from the general 
population eligible for breast 
screening (aged 40-64) 
True negative  
False positive 
True negative  
False positive 
0.91 
0.66 
0.66 
0.66 
12 months 
 
Lifelong 
VAS  
TTO 
(chain) 
Two-stage chaining method used to adjust 
temporary health states onto death-full health 
scale 
Kim  
Korea 
(93) 
Determine the utility of 
breast cancer health states 
in Korean population. 
509 general population men 
and women (aged >19) 
Treatment (intervention) of screen 
detected non-invasive, invasive or 
advanced breast cancer, recurrence, 
terminal care  
VAS: 0.170-0.681 
SG: 0.352-0.804 
Lifelong VAS, SG 8 vignettes via face-to-face interview.  
VAS anchored worst-best health (readjusted to 
dead). 
Rijnsburger  
Netherlands 
(94) 
Assess the QoL of 
screening high-risk women 
for breast cancer. 
334 women in a high-risk 
breast screening trial (mean 
age 40.9). 
Screening attendance VAS: 0.807-0.819 
EQ-5D: 0.880 
Unclear VAS, 
EQ-5D, 
SF-36 
Direct measurement at time points of 2 months 
prior, during and 1-4 weeks after attending 
screening.  
Tosteson 
USA 
(34) 
Measure the QoL impact 
of false-positive 
mammograms  
1028 women in digital breast 
screening trial: 534 = 
negative, 494 = false positive  
Screening (negative mammogram) 
Diagnosis (positive mammogram) 
VAS: 0.830-0.860 
EQ-5D: 0.900-0.910 
Unclear  EQ-5D VAS Direct measurement at baseline and up to 1 year 
after screening. 
VAS anchored worst-best imaginable health 
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